Introduction
Methods
Patient Characteristics
Patients’ characteristics | Number of cases (%) | Median (IQR) |
---|---|---|
Tumor extension in cm | 6.0 (5.0–6.5) | |
PET-positive lymph nodes |
n = 8 (80%) | |
Volume of GTV in cm3
| 20.3 (13.0–28.0) | |
Volume of PTV4 in cm3
| 387.2 (323.9–523.9) | |
Volume of PTV3 in cm3
| 349.3 (291.3–472.5) | |
Volume of PTV2 in cm3
| 310.5 (252.7–419.3) |
Treatment Planning
NTCP-Calculation
Statistics
Results
Neoadjuvant treatment
Neoadjuvant treatment (41.4 Gy)
| |||||
---|---|---|---|---|---|
PTV2 | PTV3 | PTV4 | |||
Mean ± SD | Mean ± SD | Mean ± SD |
p-Valuea
|
p-Valueb
| |
Myelon | |||||
Dmax (Gy) | 31.65 ± 4.29 | 31.99 ± 4.02 | 32.68 ± 4.13 |
0.036
| 0.173 |
Liver | |||||
Dmean (Gy) | 0.50 ± 1.01 | 0.71 ± 1.33 | 0.95 ± 1.54 |
0.020
|
0.033
|
Dmedian (Gy) | 0.18 ± 0.20 | 0.29 ± 0.39 | 0.49 ± 0.85 | 0.203 | 0.179 |
Heart | |||||
Dmin (Gy) | 0.91 ± 2.27 | 0.97 ± 2.20 | 1.03 ± 1.96 | 0.591 | 0.393 |
Dmax (Gy) | 25.95 ± 19.04 | 35.54 ± 13.99 | 41.25 ± 5.98 | 0.118 |
0.021
|
Dmean (Gy) | 6.48 ± 5.91 | 7.83 ± 6.27 | 8.83 ± 6.13 |
0.036
|
0.009
|
Dmedian (Gy) | 4.95 ± 5.19 | 6.11 ± 5.85 | 6.47 ± 5.86 | 0.256 | 0.059 |
V5 (%) | 35.81 ± 37.94 | 45.22 ± 38.64 | 53.14 ± 39.64 |
0.002
|
0.001
|
V10 (%) | 26.15 ± 29.53 | 33.25 ± 31.89 | 37.34 ± 30.39 | 0.174 |
0.016
|
V15 (%) | 13.94 ± 15.65 | 17.77 ± 17.00 | 19.59 ± 15.83 | 0.270 |
0.023
|
V20 (%) | 7.97 ± 9.09 | 10.21 ± 9.85 | 11.20 ± 9.16 | 0.295 |
0.027
|
V25 (%) | 5.05 ± 5.85 | 6.48 ± 6.30 | 7.18 ± 5.99 | 0.238 |
0.026
|
V30 (%) | 3.47 ± 4.08 | 4.43 ± 4.37 | 5.03 ± 4.30 | 0.135 |
0.021
|
V35 (%) | 2.50 ± 3.01 | 3.16 ± 3.23 | 3.69 ± 3.29 | 0.068 |
0.018
|
Lungs | |||||
Dmin (Gy) | 0.19 ± 0.12 | 0.24 ± 0.16 | 0.32 ± 0.22 |
0.007
|
0.003
|
Dmax (Gy) | 42.45 ± 0.19 | 42.48 ± 0.28 | 42.62 ± 0.52 | 0.357 | 0.340 |
Dmean (Gy) | 9.28 ± 1.85 | 10.33 ± 1.83 | 11.02 ± 1.86 |
<0.001
|
<0.001
|
Dmedian (Gy) | 6.89 ± 3.92 | 8.51 ± 3.41 | 9.60 ± 2.46 |
0.011
|
0.001
|
V5 (%) | 61.73 ± 17.57 | 69.24 ± 17.61 | 74.24 ± 18.25 |
<0.001
|
<0.001
|
V10 (%) | 42.74 ± 9.29 | 48.43 ± 9.67 | 52.59 ± 10.47 |
0.003
|
<0.001
|
V15 (%) | 20.84 ± 6.11 | 23.55 ± 6.37 | 25.42 ± 5.72 |
0.004
|
<0.001
|
V20 (%) | 9.50 ± 3.51 | 10.70 ± 3.67 | 11.41 ± 3.45 |
0.011
|
<0.001
|
V25 (%) | 4.68 ± 1.64 | 5.31 ± 1.70 | 5.64 ± 1.60 |
0.017
|
<0.001
|
V30 (%) | 2.69 ± 0.75 | 3.05 ± 0.76 | 3.25 ± 0.72 |
0.012
|
<0.001
|
V35 (%) | 1.74 ± 0.40 | 1.95 ± 0.39 | 2.08 ± 0.40 |
0.017
|
<0.001
|
Definite treatment
Definite treatment (50.4 Gy)
| |||||
---|---|---|---|---|---|
PTV2 | PTV3 | PTV4 | |||
Mean ± SD | Mean ± SD | Mean ± SD |
p-Value
a
|
p-Valueb
| |
Myelon | |||||
Dmax (Gy) | 36.49 ± 3.09 | 37.21 ± 3.04 | 37.77 ± 3.05 | 0.146 | 0.130 |
Liver | |||||
Dmean (Gy) | 0.61 ± 1.24 | 0.85 ± 1.62 | 1.16 ± 1.88 |
0.017
|
0.032
|
Dmedian (Gy) | 0.22 ± 0.25 | 0.34 ± 0.48 | 0.59 ± 1.04 | 0.196 | 0.179 |
Heart | |||||
Dmin (Gy) | 1.10 ± 2.76 | 1.18 ± 2.68 | 1.25 ± 2.39 | 0.557 | 0.384 |
Dmax (Gy) | 31.48 ± 23.31 | 40.93 ± 17.28 | 50.23 ± 7.33 | 0.056 |
0.021
|
Dmean (Gy) | 7.65 ± 7.41 | 9.26 ± 7.86 | 10.73 ± 7.48 |
0.015
|
0.003
|
Dmedian (Gy) | 6.02 ± 6.33 | 7.36 ± 7.16 | 7.86 ± 7.14 | 0.212 | 0.059 |
V5 (%) | 37.48 ± 38.56 | 45.89 ± 40.15 | 55.13 ± 39.55 |
<0.001
|
0.001
|
V10 (%) | 31.27 ± 35.49 | 37.71 ± 37.10 | 45.18 ± 36.98 |
0.008
|
0.007
|
V15 (%) | 19.52 ± 21.85 | 24.16 ± 24.36 | 27.50 ± 22.24 | 0.163 |
0.020
|
V20 (%) | 11.76 ± 13.25 | 14.52 ± 14.79 | 16.46 ± 13.39 | 0.181 |
0.024
|
V25 (%) | 7.55 ± 8.63 | 9.34 ± 9.62 | 10.60 ± 8.71 | 0.179 |
0.027
|
V30 (%) | 5.20 ± 6.02 | 6.44 ± 6.68 | 7.37 ± 6.15 | 0.145 |
0.026
|
V35 (%) | 3.78 ± 4.43 | 4.67 ± 4.89 | 5.45 ± 4.64 | 0.089 |
0.022
|
V40 (%) | 2.87 ± 3.41 | 3.52 ± 3.75 | 4.20 ± 3.67 |
0.046
|
0.019
|
V45 (%) | 2.19 ± 2.68 | 2.67 ± 2.93 | 3.23 ± 2.95 |
0.030
|
0.018
|
Lungs | |||||
Dmin (Gy) | 0.22 ± 0.15 | 0.29 ± 0.20 | 0.39 ± 0.27 |
0.004
|
0.002
|
Dmax (Gy) | 50.79 ± 2.99 | 51.72 ± 0.40 | 51.80 ± 0.67 | 0.711 | 0.313 |
Dmean (Gy) | 11.10 ± 2.48 | 12.39 ± 2.27 | 13.37 ± 2.27 |
<0.001
|
<0.001
|
Dmedian (Gy) | 8.31 ± 4.86 | 9.96 ± 4.16 | 11.65 ± 3.00 |
0.004
|
0.001
|
V5 (%) | 63.61 ± 18.19 | 70.52 ± 18.49 | 76.20 ± 18.29 |
<0.001
|
<0.001
|
V10 (%) | 50.67 ± 12.94 | 57.46 ± 13.30 | 63.33 ± 14.45 |
<0.001
|
<0.001
|
V15 (%) | 30.32 ± 8.43 | 35.01 ± 7.59 | 38.12 ± 7.26 |
0.001
|
<0.001
|
V20 (%) | 15.96 ± 5.76 | 18.42 ± 5.35 | 20.04 ± 4.95 |
0.001
|
<0.001
|
V25 (%) | 8.33 ± 3.38 | 9.62 ± 3.26 | 10.37 ± 3.11 |
0.004
|
<0.001
|
V30 (%) | 4.65 ± 1.77 | 5.42 ± 1.75 | 5.83 ± 1.63 |
0.008
|
0.001
|
V35 (%) | 2.87 ± 0.87 | 3.38 ± 0.90 | 3.63 ± 0.83 |
0.009
|
0.001
|
V40 (%) | 1.90 ± 0.56 | 2.30 ± 0.50 | 2.47 ± 0.48 |
0.011
|
0.011
|
V45 (%) | 1.23 ± 0.50 | 1.56 ± 0.30 | 1.68 ± 0.32 |
0.027
|
0.046
|
NTCP
PTV2 | PTV3 | PTV4 | |||
---|---|---|---|---|---|
Mean ± SD | Mean ± SD | Mean ± SD |
p-Valuea
|
p-Valueb
| |
Neoadjuvant treatment (41.4 Gy) | |||||
Risk of pericarditis (%) | 0.00 ± 0.00 | 0.01 ± 0.00 | 0.01 ± 0.00 | 0.183 | 0.169 |
Risk of pneumonitis (%) | 0.02 ± 0.03 | 0.04 ± 0.06 | 0.06 ± 0.08 | 0.059 |
0.031
|
Definite treatment (50.4 Gy) | |||||
Risk of pericarditis (%) | 0.00 ± 0.01 | 0.01 ± 0.02 | 0.01 ± 0.02 | 0.111 | 0.172 |
Risk of pneumonitis (%) | 0.10 ± 0.16 | 0.18 ± 0.26 | 0.29 ± 0.37 | 0.063 |
0.032
|